Bay Area's Rani Therapeutics Lands $53M as Company Moves to Clinical Trials Post author:Sam Post published:February 7, 2018 Post category:BioPharma Rani said the latest funding round brings its coffers a total of $142M. Source: BioSpace You Might Also Like Alnylam Stock Catapults as Genetic Disease Drug Meets All Phase III Goals September 19, 2017 Varian Medical Systems Gets FDA 510(k) Clearance for Halcyon Treatment System June 28, 2017 Regeneron to Terminate Its Antibody Discovery Pact With Sanofi August 2, 2017
